Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-fluoro-5-morpholin-4-yl-N-[3-(2-pyridin‑4‑ylethyl)‑1H‑indol‑5‑yl]benzamide is an experimental small molecule compound belonging to the phenylmorpholine class. It has been studied as a potential inhibitor of mitogen‐activated protein kinase 14 (MAPK14, also known as p38α MAP kinase), with reported in vitro activity (IC50 ~630 nM). There are no approved indications or clinical trials beyond preclinical/experimental status, and it is not marketed for any disease[1][7]. The compound’s mechanism of action involves inhibition of MAPK14, a kinase implicated in inflammatory and proliferative signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-fluoro-5-morpholin-4-yl-N-[3-(2-pyridin-4-ylethyl)-1H-indol-5-yl]benzamide.